-
Je něco špatně v tomto záznamu ?
Simulation of Airway Deposition of an Aerosol Drug in COPD Patients
Á. Farkas, F. Lizal, J. Jedelsky, J. Elcner, A. Horváth, M. Jicha,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
CZ.02.2.69/0.0/0.0/16_027/0008371
European Union
FSI-S-17-4444
Brno University
INTER-COST LTC17087
Ministry of Education, Youth and Sports of Czech Republic
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
- Publikační typ
- časopisecké články MeSH
Medical aerosols are key elements of current chronic obstructive pulmonary disease (COPD) therapy. Therapeutic effects are conditioned by the delivery of the right amount of medication to the right place within the airways, that is, to the drug receptors. Deposition of the inhaled drugs is sensitive to the breathing pattern of the patients which is also connected with the patient's disease severity. The objective of this work was to measure the realistic inhalation profiles of mild, moderate, and severe COPD patients, simulate the deposition patterns of Symbicort® Turbuhaler® dry powder drug and compare them to similar patterns of healthy control subjects. For this purpose, a stochastic airway deposition model has been applied. Our results revealed that the amount of drug depositing within the lungs correlated with the degree of disease severity. While drug deposition fraction in the lungs of mild COPD patients compared with that of healthy subjects (28% versus 31%), lung deposition fraction characteristic of severe COPD patients was lower by a factor of almost two (about 17%). Deposition fraction of moderate COPD patients was in-between (23%). This implies that for the same inhaler dosage severe COPD patients receive a significantly lower lung dose, although, they would need more.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19029216
- 003
- CZ-PrNML
- 005
- 20190822091711.0
- 007
- ta
- 008
- 190813s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/pharmaceutics11040153 $2 doi
- 035 __
- $a (PubMed)30939795
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Farkas, Árpád $u Centre for Energy Research, Hungarian Academy of Sciences, Konkoly-Thege M. út 29-33, 1121 Budapest, Hungary. farkas.arpad@energia.mta.hu. Energy Institute, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic. farkas.arpad@energia.mta.hu.
- 245 10
- $a Simulation of Airway Deposition of an Aerosol Drug in COPD Patients / $c Á. Farkas, F. Lizal, J. Jedelsky, J. Elcner, A. Horváth, M. Jicha,
- 520 9_
- $a Medical aerosols are key elements of current chronic obstructive pulmonary disease (COPD) therapy. Therapeutic effects are conditioned by the delivery of the right amount of medication to the right place within the airways, that is, to the drug receptors. Deposition of the inhaled drugs is sensitive to the breathing pattern of the patients which is also connected with the patient's disease severity. The objective of this work was to measure the realistic inhalation profiles of mild, moderate, and severe COPD patients, simulate the deposition patterns of Symbicort® Turbuhaler® dry powder drug and compare them to similar patterns of healthy control subjects. For this purpose, a stochastic airway deposition model has been applied. Our results revealed that the amount of drug depositing within the lungs correlated with the degree of disease severity. While drug deposition fraction in the lungs of mild COPD patients compared with that of healthy subjects (28% versus 31%), lung deposition fraction characteristic of severe COPD patients was lower by a factor of almost two (about 17%). Deposition fraction of moderate COPD patients was in-between (23%). This implies that for the same inhaler dosage severe COPD patients receive a significantly lower lung dose, although, they would need more.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lizal, Frantisek $u Energy Institute, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic. lizal@fme.vutbr.cz.
- 700 1_
- $a Jedelsky, Jan $u Energy Institute, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic. jedelsky@fme.vutbr.cz.
- 700 1_
- $a Elcner, Jakub $u Energy Institute, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic. elcner@fme.vutbr.cz.
- 700 1_
- $a Horváth, Alpár $u Chiesi Hungary Ltd., Dunavirág u. 2, 1138 Budapest, Hungary. a.horvath@chiesi.com. Department of Pulmonology, County Institute of Pulmonology, 2045 Törökbálint, Hungary. a.horvath@chiesi.com.
- 700 1_
- $a Jicha, Miroslav $u Energy Institute, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic. jicha@fme.vutbr.cz.
- 773 0_
- $w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 11, č. 4 (2019)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30939795 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190822091950 $b ABA008
- 999 __
- $a ind $b bmc $g 1434365 $s 1067676
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 11 $c 4 $e 20190401 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
- GRA __
- $a CZ.02.2.69/0.0/0.0/16_027/0008371 $p European Union
- GRA __
- $a FSI-S-17-4444 $p Brno University
- GRA __
- $a INTER-COST LTC17087 $p Ministry of Education, Youth and Sports of Czech Republic
- LZP __
- $a Pubmed-20190813